A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC).
The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Aurora, Colorado 80045, United States
Savannah, Georgia 31405, United States
Indianapolis, Indiana 46202, United States
Minneapolis, Minnesota 55455, United States
Saint Louis Park, Minnesota 55426, United States
Tulsa, Oklahoma 74146, United States
Philadelphia, Pennsylvania 19104, United States
Guangxi Zhuang Autonomous Region, 530021, China
Wuhan, 430022, China
Ostrava-Poruba, 708 52, Czechia
München, 81675, Germany
Aviano, 33081, Italy
Dalseo-gu, 41931, South Korea
Leicester, LE1 5WW, United Kingdom